UMass Chan Medical School licenses STR
The Nonhuman Primate Reagent Resource (NHPRR), part of the University of Massachusetts Medical School, and mAbsolve, developers of ...
Read More mAbsolve patent update
mAbsolve has now had patents for the STR silencing mutations granted in the United States (US12037380B2), Canada (CA3179582), ...
Read More Antibody Solutions Licenses STR from mAbsolve
Antibody Solutions have licensed our STR technology to provide their clients with access to this cutting edge technology ...
Read More mAbsolve to exhibit at Festival of Biologics 2023
mAbsolve will be exhibiting at the Festival of Biologics in Basel on the 10-12th of October. We will ...
Read More MHRA Licenses Novel Fc Silencing Technology from mAbsolve
The Medical and Healthcare products Regulatory Agency (MHRA) has licensed mAbsolves novel Fc silencing technology to produce gold ...
Read More STR technology available for antibodies generated from OmniAb platform
OmniAb have entered into a licensing agreement for STR. The agreement provides OmniAb with exclusive, sublicensable access to ...
Read More Geoff Hale confirmed as keynote speaker at AET 2023
Our CEO, Geoff Hale, has been confirmed as a keynote speaker at Antibody Engineering and Therapeutics 2023 in ...
Read More Use of STR in an Fc fusion protein being developed for COVID-19 published
Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University ...
Read More Genscript ProBio licences STR technology from mAbsolve
Genscript ProBio have licenced mAbsolves first in class solution for abolising antibody effector function to enable their worldwide ...
Read More